FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2154909756> ?p ?o ?g. }

• W2154909756 endingPage "3088" @default.
• W2154909756 startingPage "3081" @default.
• W2154909756 abstract "Purpose Thirty percent of patients treated with curative intent for localized prostate cancer (PC) experience biochemical recurrence (BCR) with rising serum prostate-specific antigen (sPSA), and of these, approximately 50% succumb to progressive disease. More discriminatory staging procedures are needed to identify occult micrometastases that spawn BCR. Patients and Methods PSA mRNA copies in pathologically normal pelvic lymph nodes (N0-PLN) from 341 localized PC patients were quantified by real-time reverse-transcriptase polymerase chain reaction. Based on comparisons with normal lymph nodes and PLN with metastases and on normalization to 5 × 10 6 glyceraldehyde-3′-phosphate dehydrogenase mRNA copies, normalized PSA copies (PSA-N) and a threshold of PSA-N 100 or more were selected for continuous and categorical multivariate analyses of biochemical failure-free survival (BFFS) compared with established risk factors. Results At median follow-up of 4 years, the BFFS of patients with PSA-N 100 or more versus PSA-N less than 100 was 55% and 77% (P = .0002), respectively. The effect was greatest for sPSA greater than 20 ng/mL, 25% versus 60% (P = .014), Gleason score 8 or higher, 21% versus 66% (P = .0002), stage T3c, 18% versus 64% (P = .001), and high-risk group (50% v 72%; P = .05). By continuous analysis PSA-N was an independent prognostic marker for BCR (P = .049) with a hazard ratio of 1.25 (95% CI, 1.001 to 1.57). By categorical analysis, PSA-N 100 or more was an independent variable (P = .021) with a relative risk of 1.98 (95% CI, 1.11 to 3.55) for BCR compared with PSA-N less than 100. Conclusion PSA-N 100 or more is a new, independent molecular staging criterion for localized PC that identifies high-risk group patients with clinically relevant occult micrometastases in N0-PLN, who may benefit from additional therapy to prevent BCR." @default.
• W2154909756 created "2016-06-24" @default.
• W2154909756 creator A5004319004 @default.
• W2154909756 creator A5008857530 @default.
• W2154909756 creator A5012386908 @default.
• W2154909756 creator A5014332392 @default.
• W2154909756 creator A5026158630 @default.
• W2154909756 creator A5034988446 @default.
• W2154909756 creator A5040340688 @default.
• W2154909756 creator A5049855958 @default.
• W2154909756 creator A5055590197 @default.
• W2154909756 creator A5066498868 @default.
• W2154909756 creator A5067715842 @default.
• W2154909756 creator A5073253375 @default.
• W2154909756 creator A5076056746 @default.
• W2154909756 creator A5082818820 @default.
• W2154909756 creator A5088556845 @default.
• W2154909756 date "2006-07-01" @default.
• W2154909756 modified "2023-10-16" @default.
• W2154909756 title "Molecular Load of Pathologically Occult Metastases in Pelvic Lymph Nodes Is an Independent Prognostic Marker of Biochemical Failure After Localized Prostate Cancer Treatment" @default.
• W2154909756 cites W1495945591 @default.
• W2154909756 cites W190857994 @default.
• W2154909756 cites W1965053728 @default.
• W2154909756 cites W1967770117 @default.
• W2154909756 cites W1970400785 @default.
• W2154909756 cites W1973315097 @default.
• W2154909756 cites W1975323370 @default.
• W2154909756 cites W1984758590 @default.
• W2154909756 cites W1988210827 @default.
• W2154909756 cites W1997832588 @default.
• W2154909756 cites W2011421001 @default.
• W2154909756 cites W2011820948 @default.
• W2154909756 cites W2012557595 @default.
• W2154909756 cites W2018998854 @default.
• W2154909756 cites W2033728504 @default.
• W2154909756 cites W2049153532 @default.
• W2154909756 cites W2058680827 @default.
• W2154909756 cites W2071879495 @default.
• W2154909756 cites W2101913998 @default.
• W2154909756 cites W2103003357 @default.
• W2154909756 cites W2104870101 @default.
• W2154909756 cites W2108776877 @default.
• W2154909756 cites W2111791000 @default.
• W2154909756 cites W2113450112 @default.
• W2154909756 cites W2114608969 @default.
• W2154909756 cites W2117792530 @default.
• W2154909756 cites W2125835130 @default.
• W2154909756 cites W2127313021 @default.
• W2154909756 cites W2131034864 @default.
• W2154909756 cites W2133377389 @default.
• W2154909756 cites W2144045094 @default.
• W2154909756 cites W2145460391 @default.
• W2154909756 cites W2152561234 @default.
• W2154909756 cites W2157872926 @default.
• W2154909756 cites W2164578725 @default.
• W2154909756 cites W2171774285 @default.
• W2154909756 cites W2246706547 @default.
• W2154909756 cites W2337912524 @default.
• W2154909756 cites W2414244717 @default.
• W2154909756 cites W2462133691 @default.
• W2154909756 cites W2470781888 @default.
• W2154909756 cites W3023689102 @default.
• W2154909756 cites W4242935595 @default.
• W2154909756 cites W4293168096 @default.
• W2154909756 cites W4320801174 @default.
• W2154909756 cites W4376848273 @default.
• W2154909756 cites W69788875 @default.
• W2154909756 doi "https://doi.org/10.1200/jco.2005.03.6020" @default.
• W2154909756 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16809733" @default.
• W2154909756 hasPublicationYear "2006" @default.
• W2154909756 type Work @default.
• W2154909756 sameAs 2154909756 @default.
• W2154909756 citedByCount "48" @default.
• W2154909756 countsByYear W21549097562012 @default.
• W2154909756 countsByYear W21549097562013 @default.
• W2154909756 countsByYear W21549097562014 @default.
• W2154909756 countsByYear W21549097562015 @default.
• W2154909756 countsByYear W21549097562016 @default.
• W2154909756 countsByYear W21549097562017 @default.
• W2154909756 countsByYear W21549097562018 @default.
• W2154909756 countsByYear W21549097562019 @default.
• W2154909756 countsByYear W21549097562020 @default.
• W2154909756 crossrefType "journal-article" @default.
• W2154909756 hasAuthorship W2154909756A5004319004 @default.
• W2154909756 hasAuthorship W2154909756A5008857530 @default.
• W2154909756 hasAuthorship W2154909756A5012386908 @default.
• W2154909756 hasAuthorship W2154909756A5014332392 @default.
• W2154909756 hasAuthorship W2154909756A5026158630 @default.
• W2154909756 hasAuthorship W2154909756A5034988446 @default.
• W2154909756 hasAuthorship W2154909756A5040340688 @default.
• W2154909756 hasAuthorship W2154909756A5049855958 @default.
• W2154909756 hasAuthorship W2154909756A5055590197 @default.
• W2154909756 hasAuthorship W2154909756A5066498868 @default.
• W2154909756 hasAuthorship W2154909756A5067715842 @default.
• W2154909756 hasAuthorship W2154909756A5073253375 @default.
• W2154909756 hasAuthorship W2154909756A5076056746 @default.
• W2154909756 hasAuthorship W2154909756A5082818820 @default.
• W2154909756 hasAuthorship W2154909756A5088556845 @default.

• next